AI-powered search engine used by two-thirds of US doctors reaches $15 billion valuation

Analysis

Why This Matters

Two-thirds of US doctors now depend on an AI tool for clinical decisions, a level of adoption that could shape diagnosis and treatment at scale.
The ad-supported business model introduces questions about influence and privacy in healthcare.
The $15 billion valuation signals investor confidence that AI can disrupt medical practice, but also invites regulatory scrutiny.

Background

OpenEvidence is one of several AI search tools aimed at clinicians, offering faster access to medical literature than traditional database searches. Its rapid growth mirrors the broader adoption of generative AI in professional settings, though few products have achieved such penetration in healthcare. The company has not publicly disclosed its advertising partners or revenue.

Key Perspectives

Daniel Nadler, OpenEvidence founder: Describes the platform as the first viral consumer internet app in healthcare, emphasizing its organic growth and utility for physicians. Medical professionals and observers: Debate the reliability of AI summaries, the potential for bias in ad-driven content, and the implications for doctor-patient trust. Critics/Skeptics: Raise concerns about data privacy, the influence of advertisers on clinical guidance, and the lack of long-term studies on AI-assisted outcomes.

What to Watch

Regulatory action from the FDA or FTC on AI medical tools and advertising practices.
Whether competitors (e.g., Epic, Google) launch comparable ad-supported clinical AI products.
Adoption rates outside the US and evidence of impact on patient outcomes.

Checked

9 claims in this story checked against 1 source: 4 supported.

Show each claim

Partly supportedThe search engine is used by two-thirds of US doctors.Ars Technica - All content: “Nearly two-thirds of US doctors are turning to an AI-powered search engine to make patient decisions”
SupportedThe AI-powered search engine has propelled OpenEvidence to a $15 billion valuation.Ars Technica - All content: “propelling a little-known tech startup to a $15 billion valuation”
Partly supportedOpenEvidence processes 42 million prompts monthly.Ars Technica - All content: “said that many of America’s 1 million physicians processed more than 42 million prompts last month.”
Partly supportedAmerica’s roughly 1 million physicians processed more than 42 million prompts on OpenEvidence last month.Ars Technica - All content: “said that many of America’s 1 million physicians processed more than 42 million prompts last month.”
Not in the sourcesNadler said, “the first viral consumer internet app in healthcare.”Ars Technica - All content: ““We’re the first viral consumer internet app in healthcare,” Nadler told the FT in an interview.”
SupportedOpenEvidence is Miami-based and was founded by serial entrepreneur Daniel Nadler in 2022.Ars Technica - All content: “Miami-based OpenEvidence, founded by serial entrepreneur Daniel Nadler in 2022”
SupportedOpenEvidence’s chatbot searches medical journals and clinical guidelines to help doctors diagnose and treat patients.Ars Technica - All content: “Doctors are using the company’s chatbot to scour medical journals and clinical guidelines to help diagnose and treat patients.”
SupportedThe ad-supported platform has grown largely by word of mouth.Ars Technica - All content: “The ads-powered platform has grown largely by word of mouth”
Partly supportedThe startup’s rapid rise prompted discussion specifically about the risks and benefits of AI clinical decisions and the implications of advertising in healthcare.Ars Technica - All content: “prompting a debate over the future of patient care”